Similar results, regarding reduced risk of AF, were also noted in a matched cohort of 14,566 GLP-1 receptor agonists (RAs) and dipeptidyl peptidase 4 (DPP-4) inhibitor pairs, followed for a median of 3.8 years. This evidence concerns the gene DPP4 and atrial fibrillation.